The stepped-up focus on cardiovascular risks for diabetes patients isn’t an accident. Drugmakers have conducted enormous trials to gauge them—and some have proven their meds can cut those risks. But it’s not just diabetes drugs. Sanofi, Regeneron and Amgen have now unveiled similar numbers on their cholesterol meds.
More: Sanofi and Amgen, eyeing boost for PCSK9 use, tout benefits for diabetes patients